Acelyrin, Inc. Expected to Post Q2 2024 Earnings of ($0.33) Per Share (NASDAQ:SLRN)

Acelyrin, Inc. (NASDAQ:SLRN – Free Report) – Equities researchers at HC Wainwright boosted their Q2 2024 EPS estimates for shares of Acelyrin in a report released on Wednesday, May 22nd. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($0.33) for the quarter, up from their previous estimate […]

Related Keywords

China ,New York ,United States ,Hidradenitis Suppurativa ,Zurcher Kantonalbank Zurich Cantonalbank ,Acelyrin Inc ,Nasdaq ,York State Common Retirement Fund ,Ameritas Investment Partners Inc ,China Universal Asset Management Co ,Wells Fargo Company ,Free Report ,Wells Fargo ,Get Free Report ,Investment Partners ,Kantonalbank Zurich Cantonalbank ,China Universal Asset Management ,Psoriatic Arthritis ,Acelyrin Daily ,